AN2 Therapeutics Inc (ANTX)
1.06
0.00 (0.00%)
USD |
NASDAQ |
Sep 27, 16:00
1.065
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics SG&A Expense (TTM): 15.02M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 15.02M |
March 31, 2024 | 14.35M |
December 31, 2023 | 14.76M |
September 30, 2023 | 14.59M |
June 30, 2023 | 14.18M |
March 31, 2023 | 14.76M |
Date | Value |
---|---|
December 31, 2022 | 12.75M |
September 30, 2022 | 10.81M |
June 30, 2022 | 9.054M |
March 31, 2022 | 6.317M |
December 31, 2021 | 4.668M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
4.668M
Minimum
Dec 2021
15.02M
Maximum
Jun 2024
11.93M
Average
14.18M
Median
Jun 2023
SG&A Expense (TTM) Benchmarks
Fulcrum Therapeutics Inc | 40.13M |
NovaBay Pharmaceuticals Inc | 11.53M |
Palatin Technologies Inc | 13.34M |
iBio Inc | 11.67M |
Theriva Biologics Inc | 5.633M |